(MOH) Molina Healthcare - Overview
Sector: Healthcare | Industry: Healthcare Plans | Exchange: NYSE (USA) | Market Cap: 9.045m USD | Total Return: -35.7% in 12m
Avg Turnover: 165M
EPS Trend: -61.7%
Qual. Beats: 0
Rev. Trend: 98.7%
Qual. Beats: 0
Warnings
Choppy
Tailwinds
No distinct edge detected
Molina Healthcare, Inc. (MOH) is a managed care organization primarily focused on providing government-sponsored healthcare programs. The company administers health plans for low-income individuals and families through Medicaid, Medicare, and state insurance marketplaces across the United States.
Operating within the Managed Health Care sub-industry, Molina utilizes a business model centered on capitation, where it receives fixed monthly payments per member from government agencies to manage medical risks and administrative costs. This sector is characterized by high regulatory oversight and sensitivity to federal and state budget allocations for social safety net programs.
Investors can further examine the companys valuation metrics and historical performance trends at ValueRay. Unlike diversified insurers that focus on employer-sponsored plans, Molina concentrates its operations on four distinct segments: Medicaid, Medicare, Marketplace, and Other, leveraging decades of experience in public sector healthcare since its founding in 1980.
- State Medicaid contract wins and renewals dictate long-term membership growth trajectories
- Medical loss ratio fluctuations significantly impact quarterly earnings and share price
- Federal and state reimbursement rate changes directly influence operating profit margins
- Expansion of Medicare Advantage enrollment drives diversification of higher-acuity revenue streams
- Regulatory shifts in state-level healthcare policy create significant geographic operational risks
| Net Income: 188.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -1.67 > 1.0 |
| NWC/Revenue: 11.40% < 20% (prev 12.19%; Δ -0.79% < -1%) |
| CFO/TA 0.02 > 3% & CFO 357.0m > Net Income 188.0m |
| Net Debt (-1.19b) to EBITDA (617.0m): -1.92 < 3 |
| Current Ratio: 1.63 > 1.5 & < 3 |
| Outstanding Shares: last quarter (51.0m) vs 12m ago -6.93% < -2% |
| Gross Margin: 9.59% > 18% (prev 11.46%; Δ -1.87% > 0.5%) |
| Asset Turnover: 275.0% > 50% (prev 255.5%; Δ 19.54% > 0%) |
| Interest Coverage Ratio: 2.12 > 6 (EBIT TTM 431.0m / Interest Expense TTM 203.0m) |
| A: 0.31 (Total Current Assets 13.3b - Total Current Liabilities 8.19b) / Total Assets 16.4b |
| B: 0.22 (Retained Earnings 3.62b / Total Assets 16.4b) |
| C: 0.03 (EBIT TTM 431.0m / Avg Total Assets 16.4b) |
| D: 0.33 (Book Value of Equity 4.08b / Total Liabilities 12.3b) |
| Altman-Z'' = 3.30 = A |
| DSRI: 0.91 (Receivables 3.42b/3.49b, Revenue 45.1b/41.9b) |
| GMI: 1.20 (GM 11.46% / 9.59%) |
| AQI: 0.97 (AQ_t 0.17 / AQ_t-1 0.17) |
| SGI: 1.08 (Revenue 45.1b / 41.9b) |
| TATA: -0.01 (NI 188.0m - CFO 357.0m) / TA 16.4b) |
| Beneish M = -2.89 (Cap -4..+1) = A |
As of June 08, 2026, the stock is trading at USD 190.86 with a total of 529,779 shares traded.
Over the past week, the price has changed by +9.94%,
over one month by -0.52%,
over three months by +30.70% and
over the past year by -35.74%.
Molina Healthcare has received a consensus analysts rating of 3.75. Therefore, it is recommended to hold MOH.
- StrongBuy: 6
- Buy: 1
- Hold: 8
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 186.6 | -2.2% |
P/E Trailing = 46.5416
P/E Forward = 32.3625
P/S = 0.2099
P/B = 2.2168
P/EG = 1.6164
Revenue TTM = 45.1b USD
EBIT TTM = 431.0m USD
EBITDA TTM = 617.0m USD
Long Term Debt = 3.77b USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 4.13b USD (from shortLongTermDebtTotal, last quarter) + Leases 180.0m
Net Debt = -1.19b USD (calculated: Debt 4.13b - CCE 5.31b)
Enterprise Value = 7.86b USD (9.04b + Debt 4.13b - CCE 5.31b)
Interest Coverage Ratio = 2.12 (Ebit TTM 431.0m / Interest Expense TTM 203.0m)
EV/FCF = 31.31x (Enterprise Value 7.86b / FCF TTM 251.0m)
FCF Yield = 3.19% (FCF TTM 251.0m / Enterprise Value 7.86b)
FCF Margin = 0.56% (FCF TTM 251.0m / Revenue TTM 45.1b)
Net Margin = 0.42% (Net Income TTM 188.0m / Revenue TTM 45.1b)
Gross Margin = 9.59% ((Revenue TTM 45.1b - Cost of Revenue TTM 40.8b) / Revenue TTM)
Gross Margin QoQ = 14.13% (prev 6.16%)
Tobins Q-Ratio = 0.48 (Enterprise Value 7.86b / Total Assets 16.4b)
Interest Expense / Debt = 4.92% (Interest Expense 203.0m / Debt 4.13b)
Taxrate = 17.54% (40.0m / 228.0m)
NOPAT = 355.4m (EBIT 431.0m * (1 - 17.54%))
Current Ratio = 1.63 (Total Current Assets 13.3b / Total Current Liabilities 8.19b)
Debt / Equity = 1.01 (Debt 4.13b / totalStockholderEquity, last quarter 4.08b)
Debt / EBITDA = -1.92 (Net Debt -1.19b / EBITDA 617.0m)
Debt / FCF = -4.73 (Net Debt -1.19b / FCF TTM 251.0m)
Total Stockholder Equity = 4.24b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.15% (Net Income 188.0m / Total Assets 16.4b)
RoE = 4.44% (Net Income TTM 188.0m / Total Stockholder Equity 4.24b)
RoCE = 5.39% (EBIT 431.0m / Capital Employed (Equity 4.24b + L.T.Debt 3.77b))
RoIC = 5.97% (NOPAT 355.4m / Invested Capital 5.95b)
WACC = 5.34% (E(9.04b)/V(13.2b) * Re(5.92%) + D(4.13b)/V(13.2b) * Rd(4.92%) * (1-Tc(0.18)))
Discount Rate = 5.92% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -88.66 | Cagr: -5.70%
[DCF] Terminal Value 73.10% ; FCFF base≈360.6m ; Y1≈316.2m ; Y5≈255.5m
[DCF] Fair Price = 101.5 (EV 4.10b - Net Debt -1.19b = Equity 5.29b / Shares 52.1m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -61.68 | EPS CAGR: -21.86% | SUE: 0.34 | # QB: 0
Revenue Correlation: 98.74 | Revenue CAGR: 14.33% | SUE: -0.68 | # QB: 0
EPS current Quarter (2026-06-30): EPS=1.47 | Chg30d=-1.60% | Revisions=-5% | Analysts=17
EPS next Quarter (2026-09-30): EPS=1.07 | Chg30d=+24.65% | Revisions=+33% | Analysts=6
EPS current Year (2026-12-31): EPS=5.21 | Chg30d=+0.92% | Revisions=+62% | GrowthEPS=-52.8% | GrowthRev=-2.2%
EPS next Year (2027-12-31): EPS=7.85 | Chg30d=+20.19% | Revisions=+67% | GrowthEPS=+126.5% | GrowthRev=+6.4%
[Analyst] Revisions Ratio: +67%